About MannKind Corp
MannKind Corp is a publicly listed company based in Los Angeles (United States) founded in 1991. Developer of small-molecule drugs. MannKind Corp has raised $50 million across 8 funding rounds from investors including Deerfield. The company has 407 employees. MannKind Corp has completed 3 acquisitions, including Qrumpharma, V-Go and scPharmaceuticals. Its chief executive, as recorded, is Michael Castagna. Its website mannkindcorp.com draws about 23 thousand monthly visits. MannKind Corp offers products and services including Afrezza, V-Go, and Technosphere. Its focus areas include Life Sciences, Drug Delivery, Inhaled and Metabolic Diseases. Its legal entity is MannKind Corporation. Its competitors include NGM Biopharmaceuticals, Rhythm Pharmaceuticals and Impel NeuroPharma; 3 of its 3 listed competitors have raised funding.
Company details
MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The companys Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The companys lead product includes Afrezza (inhalable ultra-rapid-acting insulin).
- Headquarters Los Angeles, United States
- Employees 407
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website mannkindcorp.com
- Social LinkedIn X Facebook Instagram
- Legal Name Mannkind Corporation
- Annual Revenue$348.97 M (USD)22.23as on Dec 31, 2025
- Net Profit$5.86 M (USD)-78.75as on Dec 31, 2025
- EBITDA$68.52 M (USD)-11.75as on Dec 31, 2025
- Total Equity Funding$50M (USD)
in 8 rounds
- Latest Funding Round$200M (USD), Post-IPO
Mar 2021
- Investors
- Employee Count407
- Investments & AcquisitionsQrumpharma
& 2 more
Products & Services of MannKind Corp
MannKind Corp offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere.
Inhaled insulin powder for managing diabetes effectively.
Patch device for continuous insulin administration.
Platform for delivering medications via inhalation.
Funding Insights of MannKind Corp
MannKind Corp has successfully raised a total of $50M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 8
- Last Round Post-IPO — $200M
- First Round $50M
(Jan 2004)
- Investors Count 1
All 8 funding rounds of MannKind Corp with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $200M | Post-IPO | – | – | – |
| Mar 2018 | $8.2M | Post-IPO | – | – | – |
| Jul 2013 | $40M | Debt – Venture | – | – | |
| Aug 2010 | $100M | Post-IPO | – | – | – |
| Aug 2005 | $58.9M | Debt – Venture | – | – | – |
| Aug 2005 | $175M | Post-IPO | – | – | – |
| Aug 2004 | $189.12M | Post-IPO | – | – | – |
| Jan 2004 | $50M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in MannKind Corp
MannKind Corp has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States |
Investor details for MannKind Corp
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MannKind Corp
104 people are tracked at MannKind Corp (46 in leadership, 18 in board & advisors, 40 in team); the tracked headcount is 407.
| Name | Role | Group |
|---|---|---|
Michael Castagna | CEO | Leadership |
Stuart A. Tross | Chief People and Workplace Officer | Leadership |
Karen Jaffe | VP, Regulatory Affairs & Quality Assurance | Leadership |
Traci Centofanti | Executive Director, IT | Leadership |
Stephen Woolfrey | Executive Director, Packaging Technology | Leadership |
Sanjay Singh | Executive Vice President ( Tech Operations) | Leadership |
Kalpesh Brahmskshatriya | Associate Director, Mts, Automation & Controls | Leadership |
Stephen Clark | Associate Director Manufacturing Technical Services | Leadership |
Katherine Taudvin | Vp, HR | Leadership |
Mark Warner | Associate Director - Laboratory Systems Compliance | Leadership |
Michael Tortora Chmm, Ohst, Chsp | Associate Director, Environmental Health & Safety | Leadership |
David Kendall | Chief Medical Officer | Leadership |
Russell Carson | Director, Manufacturing Technical Services | Leadership |
Helena Pereira | Head Of Trade And Distribution | Leadership |
Sharon Mox | Director Quality Engineering | Leadership |
Edyta Perkowski | Manager, HR Business Partner | Leadership |
Mshr Tanya Booke | Head Of Talent, Learning And Culture | Leadership |
John B. | Associate Director - Manufacturing Engineering, Production Maintenance | Leadership |
Kevin Finucane | Director, Engineering | Leadership |
Karen Anderson | Associate Director, Talent Acquisition | Leadership |
84 more people are available in the full profile.
Complete people profiles for MannKind Corp
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MannKind Corp
MannKind Corp is a publicly listed company on the NASDAQ with ticker symbol MNKD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Jul 2004
- Listed onNASDAQ: MNKD
- Listed entityMannKind Corporation
- Exchange sectorHealth technology
- ISINUS56400P7069
- Share price$3.05 (-2.56% on the day) · 2026-10-13
- Market capitalisation$980.7M
- Price to earnings59.3
- EPS (diluted, trailing year)$-0.14
- Volume (last session)4,394,241
Financials of MannKind Corp
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $349.0M | $5.9M | $68.5M |
| 2024 | $285.5M | $27.6M | $77.7M |
| 2023 | $199.0M | -$11.9M | $16.4M |
| 2022 | $99.8M | -$87.4M | -$62.6M |
| 2021 | $75.4M | -$80.9M | -$49.9M |
Detailed financial statements for MannKind Corp
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MannKind Corp
MannKind Corp has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Qrumpharma, V-Go and scPharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure | scpharmaceuticals.com | Lexington, United States | 2013 | Aug 2025 | •••• | |
Product site of disposable, wearable insulin patch pump for continuous and bolus insulin | go-vgo.com | Denmark | 2007 | May 2022 | •••• | |
Therapeutics for diabetes and respiratory disorders are developed. | qrumpharma.com | Doylestown, United States | 2014 | Dec 2020 | •••• |
Complete acquisition details for MannKind Corp
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MannKind Corp
7 dated milestones of MannKind Corp across 34 years, from founding to its latest funding, stage changes and deals.
- Founded MannKind Corp is founded.
- Funding First funding round of $50.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Qrumpharma.
- Funding Latest funding round, Post-IPO, of $200.0M.
- Acquisition Acquires V-Go.
- Acquisition Acquires scPharmaceuticals.
Competitors of MannKind Corp
MannKind Corp has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Rhythm Pharmaceuticals and Impel NeuroPharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. |
Detailed competitors of MannKind Corp
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MannKind Corp
The website of MannKind Corp (mannkindcorp.com) receives about 23.2K visits a month and ranks #1,557,758 among all websites worldwide, #2,076 in Biotechnology and Pharmaceuticals.
- Monthly visits23.2K
▲ 57.1% vs previous month
- Unique visitors7.1K
per month
- Global rank#1,557,758
among all websites
- Category rank#2,076
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.1
- Average visit17 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with MannKind Corp. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| merck.com | 100% | 656.8K | #78,842 | View details | |
| novartis.com | 93% | 948.8K | #58,822 | View details | |
| pfizer.com | 92% | 1.9M | #24,984 | View details | |
| roche.com | 92% | 1.3M | #42,219 | View details | |
| xoma.com | 91% | 8K | #3,718,828 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for MannKind Corp
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as MannKind Corp (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | USD 761.41 M | 500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mannkind Corp
Complete news archive for MannKind Corp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MannKind Corp
MannKind Corp was founded in 1991 and raised its 1st funding round 13 years after it was founded.
MannKind Corp is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Michael Castagna is the CEO of MannKind Corp, as recorded in our data.
MannKind Corp is a funded company, having raised a total of $50M across 8 funding rounds to date. The company's 1st funding round was a Series B of $50M, raised on Jan 2004.
MannKind Corp has 407 employees.
Annual revenue of MannKind Corp is $348.97M as on Dec 31, 2025.
MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The companys Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The companys lead product includes Afrezza (inhalable ultra-rapid-acting insulin).
MannKind Corp's top competitors include Rhythm Pharmaceuticals, NGM Biopharmaceuticals and Impel NeuroPharma.
MannKind Corp offers Afrezza, V-Go, and Technosphere.
Yes, MannKind Corp is publicly traded on NASDAQ under the ticker symbol MNKD.
MannKind Corp has made 3 acquisitions, including Qrumpharma, V-Go, and scPharmaceuticals.
MannKind Corp has 1 investor. Key investors include Deerfield.